

16 November 2020

ASX Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By electronic lodgement

Dear Ms Kostopoulos,

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Micro-X Limited (ASX:MX1) (ACN 153 273 735) (**MX1**) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Act**) that:

- (a) today it issued 2,173,914 fully paid ordinary shares at an issue price of \$0.23 per share upon conversion of 5,000 unlisted convertible notes issued by MX1 in October 2018;
- (b) the shares referred to above were issued without disclosure under Part 6D.2 of the Act;
- (c) as at the date of this notice, MX1 has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to MX1; and
 - (ii) section 674 of the Act; and
- (d) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Act that is required to be set out in this notice under section 708A(6)(e) of the Act.

Yours sincerely



Kingsley Hall
Chief Financial Officer and Company Secretary
Micro-X Limited

– ENDS –

About Micro-X

Micro-X Limited (**Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing X-ray markets and a range of new and unique security and defence applications. MX1 has two mobile digital medical X-ray systems being sold commercially for diagnostic healthcare applications and Micro-X medical products are now in operation in 14 countries around the world.

For personal use only

Micro-X has a portfolio of innovative products in development, including the MBI for imaging Improvised Explosive Devices in security, defence and counter-terrorism applications; a next-generation self-service X-Ray Airport Checkpoint Portal with an integrated body scanner; and a lightweight brain CT imager for early stroke diagnosis in ambulances. Micro-X has its core R&D, engineering and production capability in Adelaide, Australia with a fully in-sourced CNT tube manufacturing line and approximately 95% Australian locally manufactured content.

CONTACTS

Micro-X Limited	Investor Enquiries
<p>Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com</p>	<p>David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com</p>

For personal use only